이상반응 보고
| VAERS ID | 2089874 |
|---|---|
| 성별 | 여성 |
| 나이 | 35세 |
| 주 코드 | NM |
| 제약회사 | PFIZER\BIONTECH |
| 로트 번호 | |
| 예방접종 횟수 | 2 |
| 접종일 | 2021-07-29 |
| 발병일 | 2021-07-29 |
| 상태 |
증상
- 고혈압(Hypertension)
- 임신 중 모성 노출(Maternal exposure during pregnancy)
이환 중 질병
지병
기타 의료
이전 예방접종
알레르기
임상 검사
증상 상세
Hypertension; Maternal Exposure During Pregnancy, second trimester; This is a spontaneous report received from contactable reporter(s) (Other HCP).
The reporter is the patient.
A 35 year-old female patient (pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 29Jul2021 08:15 (Batch/Lot number: unknown) at the age of 35 years as dose 2, single for covid-19 immunisation.
Date of last menstrual period: 02Apr2021.
The patient was 16 weeks pregnant at the time of exposure to bnt162b2.
The patient was 17 weeks pregnant at the event onset.
The patient is expected to deliver a baby(s) on 07Jan2022.
The patient's relevant medical history and concomitant medications were not reported.
Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Anatomical location: Arm right; Administration time: 08:15;), administration date: 08Jul2021, when the patient was 35 years old, for COVID-19 immunisation, reaction(s): "Maternal exposure during pregnancy, second trimester".
The following information was reported: MATERNAL EXPOSURE DURING PREGNANCY (non-serious) with onset 29Jul2021 08:15, outcome "unknown", described as "Maternal Exposure During Pregnancy, second trimester"; HYPERTENSION (non-serious) with onset 30Jul2021 11:00, outcome "not recovered", described as "Hypertension".
The event "hypertension" was evaluated at the physician office visit.
Therapeutic measures were taken as a result of hypertension.
Additional information: The patient had no known allergies.
The last menstrual period of the patient was 02Apr2021.
Prior to the vaccination, the patient was not diagnosed with COVID-19.
The patient did not receive any other vaccines within four weeks prior to the vaccination.
On 30Jul2021 at 11:00 (also reported as about 24 hours after second dose), the patient had hypertension.
At the time of report, hypertension had not yet returned to normal levels.
The event resulted in doctor or other healthcare professional office/clinic visit.
Since the vaccination, the patient had not been tested for COVID-19.
Therapeutic measures were taken as a result of hypertension which included treatment with nifedipine (MANUFACTURER UNKNOWN).
The clinical outcome of the event hypertension was not recovered at the time of this report.
The lot number for bnt162b2 was not provided and will be requested during follow up.